Literature DB >> 15520818

Functional genomics to new drug targets.

Richard Kramer1, Dalia Cohen.   

Abstract

The completion of the sequencing of the human genome, and those of other organisms, is expected to lead to many potential new drug targets in various diseases, and it is predicted that novel therapeutic agents will be developed against such targets. The role of functional genomics in modern drug discovery is to prioritize these targets and to translate that knowledge into rational and reliable drug discovery. Here, we describe the field of functional genomics and review approaches that have been applied to drug discovery, including RNA profiling, proteomics, antisense and RNA interference, model organisms and high-throughput, genome-wide overexpression or knockdowns, and outline the future directions that are likely to yield new drug targets from genomics.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15520818     DOI: 10.1038/nrd1552

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  29 in total

1.  Bottlenecks caused by software gaps in miRNA and RNAi research.

Authors:  Sean Ekins; Ron Shigeta; Barry A Bunin
Journal:  Pharm Res       Date:  2012-02-24       Impact factor: 4.200

2.  Genomics drugs in clinical trials.

Authors:  Jonathan Hall; Patrick Dennler; Stephanie Haller; Anna Pratsinis; Katharina Säuberli; Harry Towbin; Katja Walther; Katja Walthe; Janine Woytschak
Journal:  Nat Rev Drug Discov       Date:  2010-12       Impact factor: 84.694

3.  Advances in Nuclear Magnetic Resonance for Drug Discovery.

Authors:  Robert Powers
Journal:  Expert Opin Drug Discov       Date:  2009-10-01       Impact factor: 6.098

Review 4.  Proof of concept: network and systems biology approaches aid in the discovery of potent anticancer drug combinations.

Authors:  Asfar S Azmi; Zhiwei Wang; Philip A Philip; Ramzi M Mohammad; Fazlul H Sarkar
Journal:  Mol Cancer Ther       Date:  2010-11-01       Impact factor: 6.261

5.  Update of TTD: Therapeutic Target Database.

Authors:  Feng Zhu; BuCong Han; Pankaj Kumar; XiangHui Liu; XiaoHua Ma; Xiaona Wei; Lu Huang; YangFan Guo; LianYi Han; ChanJuan Zheng; YuZong Chen
Journal:  Nucleic Acids Res       Date:  2009-11-20       Impact factor: 16.971

Review 6.  Structural Variability in the RLR-MAVS Pathway and Sensitive Detection of Viral RNAs.

Authors:  Qiu-Xing Jiang
Journal:  Med Chem       Date:  2019       Impact factor: 2.745

7.  Multiplexed mass cytometry profiling of cellular states perturbed by small-molecule regulators.

Authors:  Bernd Bodenmiller; Eli R Zunder; Rachel Finck; Tiffany J Chen; Erica S Savig; Robert V Bruggner; Erin F Simonds; Sean C Bendall; Karen Sachs; Peter O Krutzik; Garry P Nolan
Journal:  Nat Biotechnol       Date:  2012-09       Impact factor: 54.908

Review 8.  Solid-phase and microwave-assisted syntheses of 2,5-diketopiperazines: small molecules with great potential.

Authors:  Jennifer C O'Neill; Helen E Blackwell
Journal:  Comb Chem High Throughput Screen       Date:  2007-12       Impact factor: 1.339

9.  Gephyrin selective intrabodies as a new strategy for studying inhibitory receptor clustering.

Authors:  Paola Zacchi; Elena Dreosti; Michela Visintin; Matteo Moretto-Zita; Ivan Marchionni; Isabella Cannistraci; Zeynep Kasap; Heinrich Betz; Antonino Cattaneo; Enrico Cherubini
Journal:  J Mol Neurosci       Date:  2007-11-16       Impact factor: 3.444

10.  Assessing the druggability of protein-protein interactions by a supervised machine-learning method.

Authors:  Nobuyoshi Sugaya; Kazuyoshi Ikeda
Journal:  BMC Bioinformatics       Date:  2009-08-25       Impact factor: 3.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.